As a result, various new agents have been combined with CHOP, including anti-CD52 monoclonal antibody (alemtuzumab), proteasome inhibitor (bortezomib), anti-vascular endothelial growth factor antibody (bevacizumab), denileukin diftitox, and mTOR inhibitor (everolimus), in order to augment the efficacy of CHOP chemotherapy in newly diagnosed PTCL patients [14–18]. This evidence concerns the gene MTOR and mature T-cell and NK-cell non-Hodgkin lymphoma.